Castle Biosciences (NASDAQ:CSTL) Stock: Insider Tobin Juvenal Sells 3,288 Shares

Castle Biosciences, Inc. (NASDAQ:CSTL) insider Tobin Juvenal sold 3,288 shares of Castle Biosciences stock in a transaction that occurred on Monday, October 26th. The shares were sold at an average price of $33.08, for a total value of $108,767.04. Following the sale, the insider directly owned 45,431 shares in the company, valued at approximately $1,502,857.48. This trade represents a 6.75% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Castle Biosciences Price Performance

Shares of CSTL stock opened at $38.51 on Friday. Castle Biosciences, Inc. has a 12-month low of $17.72 and a 12-month high of $44.28. The company has a debt-to-equity ratio of 0.02, a current ratio of 6.04 and a quick ratio of 5.85. The business has a 50 day simple moving average of $34.13 and a 200 day simple moving average of $28.69.

Castle Biosciences (NASDAQ:CSTL) last announced its earnings results on Thursday, July 30th. The company reported ($0.07) earnings per share for the quarter, beating the consensus estimate of ($0.41) by $0.34. Castle Biosciences had a negative return on equity of 4.15% and a negative net margin of 5.43%. The firm had revenue of $99.86 million for the quarter, compared to the consensus estimate of $86.23 million. Sell-side analysts anticipate that Castle Biosciences, Inc. will post -1.29 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on CSTL. Robert W. Baird set a $36.00 price objective on shares of Castle Biosciences in a research note on Friday, July 31st. BTIG Research increased their price objective on shares of Castle Biosciences from $40.00 to $44.00 and gave the company a “buy” rating in a report on Monday, August 3rd. Weiss Ratings upgraded shares of Castle Biosciences from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, July 31st. Mizuho assumed coverage on shares of Castle Biosciences in a research note on Thursday. They set an “outperform” rating and a $60.00 price objective on the stock. Finally, Wall Street Zen cut Castle Biosciences from a “buy” rating to a “hold” rating in a report on Saturday, October 24th. One research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $44.25.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the company. NFSG Corp bought a new stake in Castle Biosciences in the third quarter worth about $36,000. Global Retirement Partners LLC acquired a new stake in Castle Biosciences in the 2nd quarter valued at about $26,000. Mirae Asset Global Investments Co. Ltd. bought a new position in shares of Castle Biosciences during the 3rd quarter valued at about $55,000. Quantbot Technologies LP bought a new position in shares of Castle Biosciences during the 2nd quarter valued at about $62,000. Finally, State of Wyoming bought a new position in shares of Castle Biosciences during the 2nd quarter valued at about $117,000. Institutional investors own 92.60% of the company’s stock.

About Castle Biosciences

Castle Biosciences, Inc is a molecular diagnostics company that develops and commercializes tests designed to help physicians diagnose cancer, assess disease risk and guide treatment decisions. The company focuses on conditions in which additional biological information can complement traditional pathology and clinical assessment.

Its portfolio includes DecisionDx-Melanoma, which helps evaluate the risk of metastatic recurrence in patients with cutaneous melanoma; DecisionDx-SCC, which assesses metastatic risk in cutaneous squamous cell carcinoma; and DecisionDx-UM, a test for determining metastatic risk in uveal melanoma.